Consensus Takeda Pharmaceutical Company Limited

Stocks

4502

JP3463000004

Pharmaceuticals

Market Closed - Japan Exchange 07:30:00 23/10/2026 BST			5-day change	1st Jan Change
6,389.00 ^JPY	+0.65%		+2.67%	+32.14%

10-23	Takeda Pharmaceutical Company Limited Announces Positive Results From Phase 3 G-HOPE-001 Study Of Arcotatug Tavatecan In Advanced Gastric Cancer	CI
10-23	Takeda Cancer Drug Extends Survival in Phase 3 Gastric Cancer Trial	MT

Evolution of the Average Target: Takeda Pharmaceutical Company Limited

Evolution of the Target Price: Takeda Pharmaceutical Company Limited

Changes in Analyst Recommendations: Takeda Pharmaceutical Company Limited

14965dd762a22d303490502c55a87._EkD0XKQhh09rQ4wTrdfEqM6AQMT4G7wLl1W8orPwU8.mSJGlwbV4Wdix0pYY9EuX-gMR2xm1ijCRzxgmNCV-ADJJnCpOMjrRGrcRw~39a2e7d503aec7ab94f0ec64ac16a8cf

Analysts' recommendations: Takeda Pharmaceutical Company Limited

08-31	Protagonist Therapeutics' Own Pipeline Seen as Main Long-Term Growth Driver, Wedbush Says	MT
07-28	SBI Securities Starts Takeda Pharmaceutical at Neutral with 5,400 Yen Price Target	MT
07-24	China Merchants Starts Takeda Pharmaceutical at Buy with 6,600 Yen Price Target	MT
03-30	Alumis' Drug 'Very Positive' for Treatment of Psoriasis, Systemic Lupus Erythematosus, Oppenheimer Says	MT
01-30	Jefferies Adjusts Takeda Pharmaceutical's Price Target to 5,700 Yen From 5,100 Yen, Keeps at Buy	MT
11-11	Neurocrine Biosciences' Depressive Disorder Drug Fails to Meet Primary Goal in Phase 2 Study	MT
26/09/25	Alkermes' Stock Dip on Narcolepsy Data Seen as Buying Opportunity, RBC Says	MT
20/08/25	Veeva Systems Q2 Results Likely In-Line to Better, Maintain H2 Outlook, Truist Says	MT
09/05/25	Jefferies Adjusts Takeda Pharmaceutical's Price Target to 5,100 Yen From 5,500 Yen, Keeps at Buy	MT
06/05/25	Jefferies Adjusts Takeda Pharmaceutical Company's Price Target to 5,500 Yen From 5,000 Yen, Keeps at Buy	MT
12/08/24	Jefferies Adjusts Takeda Pharmaceutical's Price Target to 5,000 Yen From 4,800 Yen, Keeps at Buy	MT
31/07/24	Jefferies Adjusts Takeda Pharmaceutical's Price Target to 4,800 Yen From 5,600 Yen, Keeps at Buy	MT
13/02/24	Jefferies Adjusts Takeda Pharmaceutical's Price Target to 5,600 Yen From 5,200 Yen, Keeps at Buy	MT
03/10/23	Jefferies Adjusts Takeda Pharmaceutical’s Price Target to 5,200 Yen From 5,300 Yen, Keeps at Buy	MT
22/09/23	Jefferies Adjusts Takeda Pharmaceutical’s Price Target to 5,300 Yen From 5,100 Yen, Keeps at Buy	MT
31/05/23	Jefferies Adjusts Takeda Pharmaceutical’s Price Target to 5,100 Yen From 5,000 Yen, Keeps at Buy	MT
16/05/23	TD Cowen Adjusts Price Target on Takeda Pharmaceutical to $20 From $30, Maintains Outperform Rating	MT
04/04/23	TD Cowen Adjusts Price Target on Takeda Pharmaceutical to $30 From $24, Keeps Outperform Rating	MT
16/03/23	BofA Securities Upgrades Takeda Pharmaceutical to Buy From Neutral, Price Target $20	MT
06/03/23	Jefferies Adjusts Takeda Pharmaceutical’s Price Target to 5,000 Yen From 4,600 Yen, Keeps at Buy	MT
01/08/22	Jefferies Downgrades Takeda Pharmaceutical to Hold From Buy	MT
19/07/22	Cowen Upgrades Takeda Pharmaceutical to Outperform From Market Perform	MT
07/10/21	Takeda Pharmaceutical : Morgan Stanley Downgrades Takeda Pharmaceutical to Equal-weight From Overweight	MT
08/09/17	Bayer : Germany's Merck hires JP Morgan to sell consumer health	RE

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	TAKEDA PHARMACEUTICAL COMPANY LIMITED					+4.63%
	ELI LILLY AND COMPANY					+4.56%
	JOHNSON & JOHNSON					+5.91%
	ABBVIE INC.					-0.3%
	ROCHE HOLDING AG					-1.29%
	MERCK & CO., INC.					+9.97%
	NOVARTIS AG					-3.4%
	ASTRAZENECA PLC					+22.47%
	AMGEN INC.					-9.69%
	GILEAD SCIENCES, INC.					+2.66%
	Average					+3.55%
	Weighted average by Cap.					+3.78%